Production (Stage)
Genocea Biosciences, Inc.
GNCAQ
$0.00
$0.000.00%
OTC PK
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Net Income | -33.34% | 11.38% | 20.48% | 61.92% | 6.77% |
| Total Depreciation and Amortization | 4.99% | 11.25% | 27.65% | 32.50% | 38.04% |
| Total Amortization of Deferred Charges | -- | 16.67% | -- | -- | -- |
| Total Other Non-Cash Items | 1,858.93% | -79.03% | -22.31% | -2,497.70% | 72.55% |
| Change in Net Operating Assets | 16.19% | -31.37% | -149.54% | 281.88% | 27.59% |
| Cash from Operations | -22.72% | -15.17% | -36.92% | -6.01% | 10.17% |
| Capital Expenditure | 13.35% | 31.80% | 20.18% | -125.24% | -375.97% |
| Sale of Property, Plant, and Equipment | -66.15% | 275.00% | -100.00% | -100.00% | 306.25% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 10.06% | 32.70% | 19.70% | -129.58% | -381.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 91.06% | -5,334.78% | 100.00% | 100.00% | -30,973.33% |
| Issuance of Common Stock | -90.48% | -52.30% | -99.46% | -4.59% | 823.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -190.57% | -91.60% | -99.46% | -4.05% | -175.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.86% | -49.69% | -117.54% | -28.06% | -0.85% |